The current standard conditioning regimen before auto-SCT in patients with multiple myeloma is melphalan 200 mg/m 2 . Several attempts have recently been made to improve this aspect of the high-dose therapy procedure. The scope of this review article is to summarize current knowledge on conditioning regimens in this setting.
Introduction
High-dose therapy (HDT) followed by auto-SCT is considered the standard of care in the frontline treatment of newly diagnosed patients with multiple myeloma (MM) up to 65 years of age. 1 Following the introduction of the novel agents, thalidomide, bortezomib and lenalidomide, over the last 10 years, the results of this procedure have improved. 1, 2 There is a growing body of evidence showing an association between depth of response to therapy and long-term outcome. 3, 4 Novel agents are routinely used before auto-SCT as part of induction therapy to increase the response rates before HDT. 1, 2 These novel agents have also been added after auto-SCT as consolidation therapy to further increase the quality of response. 1, 5, 6 Finally, recent data suggest that it is now possible to prolong the duration of the first remission by using novel agents as maintenance therapy. 1, [7] [8] [9] [10] [11] Although many studies have been performed in the induction, consolidation and maintenance settings, few trials have been dedicated to conditioning regimens before auto-SCT. Nevertheless, several attempts have recently been made to improve this aspect of the HDT procedure. The aim of this article is to summarize the current knowledge on conditioning regimens before auto-SCT and to review the more recent data in this setting.
Melphalan 200 as standard of care
The current standard conditioning regimen is melphalan 200 mg/m 2 (Mel200) IV. This regimen was first introduced by the London group in the early 1990s in an open series of 53 patients. 12 At that time, TBI was still the most frequently used preparative regimen for auto-SCT, based on the experience of the Arkansas group. 13 In the prospective, randomized Intergroupe Francophone du Mye´lome (IFM) 90 trial, which demonstrated for the first time the superiority of HDT over conventional therapy in a series of 200 patients, the conditioning regimen before auto-SCT consisted of 8 Gy TBI plus melphalan 140 mg/m 2 (Mel140/ TBI).
14 Other studies undertook comparisons of conditioning regimens, but most of these were based on data from international 15 or national 16 registries and not on prospective randomized trials. The IFM group was the first to initiate such a trial comparing Mel200 to melphalan 140 mg/m 2 plus 8 Gy TBI (Mel140/TBI). 17 A total of 282 patients with newly diagnosed MM were prospectively randomized and 140 were treated with Mel140/TBI (arm A) and 142 with Mel200 (arm B). Disease response to four cycles of VCR-adriamycine and dexamethasone before randomization and auto-SCT was identical in the two arms. In arm B, hematologic recovery was significantly faster regarding both the duration of neutropenia and thrombocytopenia. In addition, transfusion requirements were significantly lower, and the median duration of hospitalization was significantly shorter in arm B. The incidence of severe mucositis was significantly increased in arm A, and five toxic deaths (3.6%) were observed in this arm, as compared with none in arm B. Following HDT, the complete response (CR), very good partial response (VGPR) and partial response rates were comparable in the two arms. Furthermore, the median duration of EFS was similar (21 vs 20.5 months), but the 45-month survival rate was 65.8% in arm B vs 45.5% in arm A (P ¼ 0.05). This difference was attributed, in part, to the use of better salvage regimens after relapse in patients treated with Mel200. The results from the trial suggested that Mel200 was at least as effective as Mel140/TBI, but that it was a less toxic conditioning regimen. Melphalan 200 mg/m 2 therefore became the preferred preparative regimen.
Alternative chemotherapy-based conditioning regimens
A variety of strategies have been explored with the aim of improving the results of Mel200, including dose escalation, addition of other agents or, conversely, dose reduction as part of a tandem auto-SCT procedure.
Higher doses of melphalan before auto-SCT have been tested, as the non-hematologic toxicity of the agent is low. In a phase I dose-escalation study, Phillips et al. investigated incremental increases of 20 mg/m 2 from a melphalan starting dose of 220 mg/m 2 and demonstrated that the maximum tolerated dose of melphalan was 280 mg/m 2 when used in combination with the cryoprotective agent amifostine. 18 Only 18 of the 58 patients examined in this series presented with MM, which was mainly of advanced nature before auto-SCT, and it was therefore not possible to draw any conclusion regarding clinical outcome or to define the anti-tumor efficacy of this regimen. Another small phase II study showed encouraging results with melphalan 220 mg/m 2 , followed by auto-SCT in relapsed/ refractory patients. 19 The regimen was generally tolerable, the most frequent adverse event being severe mucositis. To further increase response rate without increasing toxicity of HDT, a combination of anti-interleukin-6 MoAb and dexamethasone was subsequently added to melphalan 220 mg/m 2 in 16 patients with advanced MM. 20 A strong inhibition of interleukin-6 activity was observed in all patients and was correlated with the high CR rate achieved with this combination therapy. Melphalan 220 mg/m 2 þ /À anti-interleukin-6 MoAb was then used as preparative regimen for a second auto-SCT step in high-risk de novo MM in the IFM 99-04 protocol. 21 Again, the most frequent adverse event was found to be grade 3-4 mucositis. Overall results with two courses of HDT plus auto-SCT (Mel200 followed by melphalan 220 mg/m 2 ) were very encouraging in this subgroup of high-risk patients (EFS 30 months), but the addition of anti-interleukin-6 MoAb to the second conditioning regimen did not improve either OS or EFS. Overall, in the absence of a randomized trial comparing melphalan at 200 mg/m 2 vs 220 mg/m 2 , the impact of the higher dose is unknown.
The addition of another cytotoxic agent has also not resulted in convincing improvements as the apparent increase in anti-myeloma activity occurred at the expense of increased toxicity. In the Spanish PETHEMA/ GEM2000 trial, the first 225 patients who were enrolled in the study received the combination of oral BU 12 mg/kg plus melphalan 140 mg/m 2 (BuMel), but because of a high frequency of veno-occlusive disease, the protocol was amended 22 and the following 542 patients received Mel200 (ref. 23 ). The investigators subsequently compared the outcome of the two cohorts of patients, and found that the TRM was significantly increased in the BuMel group because of veno-occlusive disease. Although the median PFS was significantly longer with BuMel, survival was similar in both cohorts. Since then, BU IV has become available, and this formulation may reduce toxicity and result in greater efficacy. However, further investigation is needed.
Other conditioning regimens using alkylators have been proposed in the past on small numbers of patients, such as thiothepa-BU-CY 24 or high-dose topotecan-melphalan-CY, 25 but none of them has been compared prospectively with Mel200, and there is no evidence of superiority of these regimens over Mel200.
In a recent article, Palumbo et al reported the results of a phase 3 randomized trial that was performed in Italian centers between 2001 and 2006 and that assessed tandem HDT with two doses of melphalan, 100 or 200 mg/m 2 , before each of the auto-SCT steps, in patients with newly diagnosed MM. 26 The hypothesis was that the administration of a sequence of reduced-intensity conditioning regimens would be better tolerated, particularly in older patients, than the administration of a sequence of intensive preparative regimens aimed at providing maximum myeloma cell eradication before auto-SCT. The study was powered to demonstrate a 20% improvement in survival in 320 patients up to the age of 65 years. However, owing to slow accrual, only 298 patients participated in the trial. Median OS did not differ between the two arms of the trial, but median PFS was in favor of tandem Mel200 (31.4 vs 26.2 months; P ¼ 0.01). Of note, the 50% reduction in melphalan dose did not reduce mortality (3% in each group), hospitalization after engraftment or duration of severe (grade 3-4) neutropenia. Therefore, strategies aimed at reducing the burden of treatment, which is associated with high-dose melphalan, may need to go beyond dose reduction.
Radionuclide plus Mel200
Another strategy that has been explored in an attempt to enhance the activity of HDT before auto-SCT is the addition of a radionuclide to high-dose melphalan.
Giralt et al. reported the results of a combination of holmium 166 ( 166 Ho-DOTMP), a radiotherapeutic that localizes specifically to the skeleton and can deliver highdose radiation to the bone and BM, with either high-dose melphalan alone (Mel140 or Mel200) or Mel140/TBI. 27 In a phase 1/2 dose-escalation study of high-dose 166 Ho-DOTMP plus melphalan, a total of 83 patients received a therapeutic dose of 166 Ho-DOTMP to deliver a nominal radiation dose of 20, 30 or 40 Gy to the BM. CR rates achieved after the procedure were encouraging (23% in primary refractory patients and 40% in first remission consolidation cases), but long-term follow-up of the patients revealed two main late toxicities: grade 2-3 hemorrhagic cystitis described in 23 patients and renal toxicity of grade 3 or higher observed in 14 cases, with 8 patients developing a severe form of sustained renal impairment associated with microangiopathic hemolytic anemia, thrombocytopenia, uncontrolled hypertension and elevated lactate dehydrogenase. This delayed toxicity is an important drawback of this conditioning regimen precluding its routine use.
Another b-emitter, 153 samarium ( 153 Sm), conjugated with the diphosphonate compound EDTMP in the radiopharmaceutical 153 
Sm-EDTMP, which avidly concentrates in
Conditioning regimens in multiple myeloma P Moreau et al bone, has also been investigated in MM patients in combination with high-dose melphalan. In a phase 1 study, a total of 12 patients received escalating doses of 153 Sm-EDTMP (n ¼ 3 per group; 6, 12, 19.8 and 30 mCi/kg) and a fixed dose of Mel200, followed by auto-SCT. 28 No doselimiting toxicity was seen, and to better standardize the marrow compartment radiation dose, the study was modified such that an additional six patients were treated at the targeted absorbed radiation dose to the red marrow of 40 Gy, based on a trace-labeled infusion 1 week before the therapy. No delayed toxicity was observed, and the overall response rate was 94%, including seven VGPR and five CR. Subsequently, a total of 46 patients (29 in first response and 17 with relapsed or refractory disease) were enrolled in the phase 2 study investigating the same combination calculated to deliver 40 Gy to the BM before Mel200 and auto-SCT. 29 Before Mel200 infusion, the adverse events attributable to the radioisotope were mild and manageable. After transplant, 33% of patients had achieved a CR and another 26% had achieved VGPR. Study patients were compared with 102 patients who were simultaneously treated off study with single-agent highdose melphalan conditioning, and no difference regarding response rates, PFS or OS among patients treated with or without 153 Sm-EDTMP was seen. The authors conclude that this regimen warrants further study in the phase III setting.
Novel agents included in the conditioning regimen
Synergistic effects between bortezomib, the first-in-class proteasome inhibitor, and melphalan have been reported both in vitro 30 and in vivo. 31 Combining bortezomib and high-dose melphalan is consequently a logical and attractive approach to improving the efficacy of the conditioning regimen. Furthermore, the combination is expected to be safe because bortezomib and melphalan do not share common toxicities. These observations formed the basis for a phase 2 trial conducted by the IFM which was aimed at evaluating CR and VGPR rates, as well as toxicity of the combination of bortezomib and melphalan administered as a conditioning regimen. A total of 54 newly diagnosed patients received bortezomib (1 mg/m 2 Â 4) and Mel200 (Bor-HDM), 32 and overall, 70% of patients achieved at least a VGPR, including 17 patients in CR (32%) after auto-SCT. No toxic deaths were observed and bortezomib did not increase hematologic toxicity. Only one case of grade 3-4 peripheral neuropathy was reported. A matched control analysis was conducted comparing this cohort with patients from the IFM 2005-01 trial who were treated with Mel200 single-agent before HDT. 33 Patients were matched for response to induction therapy and type of induction, and CR was found to be higher in the group receiving Bor-HDM conditioning (35% vs 11%; P ¼ 0.001), regardless of induction therapy. The results suggest that Bor-HDM is a safe and promising conditioning regimen. These findings were recently confirmed in the relapse setting in a small series of heavily pretreated patients 34 and in a similar phase I/II trial performed in the United States in 39 patients. 35 In this latter trial, only patients who did not achieve a VGPR following one or more induction regimens were enrolled and were randomized to receive a single escalating dose of bortezomib (1.0, 1.3 or 1.6 mg/m 2 ) either 24 h before or 24 h after Mel200. No severe adverse effects were reported, and the overall response rate was 87%, with 51% achieving VGPR or better.
Arsenic trioxide is also synergistic with ascorbic acid and melphalan against myeloma both in vitro and in vivo. 36 The MD Anderson group tested this combination as a preparative regimen in 48 patients undergoing auto-SCT for MM in a phase II study. 36 Overall response rate was 85%, and median PFS was 25 months. Addition of arsenic trioxide and ascorbic acid was safe and well tolerated. This preparative regimen deserves further evaluation.
Conclusions
Taken together, the available data confirm that Mel200 should continue to be considered the gold standard conditioning regimen for patients undergoing auto-SCT for MM. 37 Nevertheless, avenues aimed at further improving response rates following auto-SCT have been opened. The most exciting areas of research involve the combination of Mel200 with novel agents, such as bortezomib, or with radionuclides, such as 153 Sm-EDTMP, whereas some investigators would favor the combination of Mel200 with other chemotherapeutic agents, such as IV BU. These combinations should be tested in future randomized trials.
